Porcellotti S, Fanelli F, Fracassi A, Sepe S, Cecconi F, Bernardi C, et al. Oxidative Stress during the Progression of β-Amyloid Pathology in the Neocortex of the Tg2576 Mouse Model of Alzheimer's Disease. Oxid Med Cell Longev. 2015;2015:967203 pubmed publisher

Sieczkowski E, Milenkovic I, Venkataramani V, Giera R, Ströbel T, Höftberger R, et al. I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies. J Alzheimers Dis. 2015;44:103-14 pubmed publisher

Bayer T, Wirths O. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. Acta Neuropathol. 2014;127:787-801 pubmed publisher

Wirths O, Hillmann A, Pradier L, Hartig W, Bayer T. Oligomeric pyroglutamate amyloid-? is present in microglia and a subfraction of vessels in patients with Alzheimer's disease: implications for immunotherapy. J Alzheimers Dis. 2013;35:741-9 pubmed publisher

Venkataramani V, Wirths O, Budka H, Hartig W, Kovacs G, Bayer T. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-? in a fraction of amyloid-? deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. J Alzheimers Dis. 2012;29:361-71 pubmed publisher

Bayer T, Wirths O. Intraneuronal A? as a trigger for neuron loss: can this be translated into human pathology?. Biochem Soc Trans. 2011;39:857-61 pubmed publisher

Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, et al. Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem. 2010;285:41517-24 pubmed publisher